Abstract: A method of validating parameters of a request from a Web client to a Web application. The validation rules are sent to a Web client, together with a response to a Web client. The parameters in a response are updated by the Web client. The updated parameters are sent in a subsequent request to the Web client, along with the validation rules. The updated parameters are validated using the validation rules in the request, thus achieving stateless validation. The validation rules are preferably digitally signed.

Abstract: A method of controlling data transfer between a Web client and a Web application by building a response with a target. The target indicates a destination to an impromptu component of the Web application. The target is signed when a response is built. After receiving the response by the Web client; the corresponding a request from the Web client includes the signed target. The request is received by an entry point of the Web application. The entry point has existing validation rules. The validation rules are by-passed when the signed target is verified. The target is restored in the request to the original state; and dispatched to the impromptu component.

Abstract: A mechanism is provided for synchronizing a first user session and a second user session in a client-server system. The first user session is between a first Web service and a client and the second user session is between a second Web service and the same client. A request is received with a first session value by the second Web service. An indicator of the first session value is assigned to a shadow, and the shadow is sent in a response to the client. A subsequent request with the shadow and a subsequent session value is received from the client. The indicator is used to verify the subsequent session value at the second Web service. The second user session is terminated if the indicator in the shadow does not correspond to the subsequent session value.

Abstract: The present invention provides inhibitors of kinases, specifically I?B kinases, JAK1, JAK2, JAK3 and TYK2. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting said kinase activity by administering the compound to a patient in need of treatment for myeloproliferative disorders, cancer or NF-?B-mediated diseases.

Abstract: Method and system for centralized control of data transfers between a Web client and a Web application by receiving a response from the Web application. After determining an offending character is present, cloaking the response from the Web application to a request from a Web client, and sending the cloaked response to the Web client through a security product which otherwise rejects the offending character.

Abstract: The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups, and their use in treating cardiovascular events and renal insufficiency.

Abstract: The present invention relates to biphenyl-based renin inhibitor compounds having amino-terminal groups, and their use in treating cardiovascular events and renal insufficiency.

Abstract: Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, C?CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

Abstract: The present invention relates to biphenyl-based renin inhibitor compounds having amino-terminal groups, and their use in treating cardiovascular events and renal insufficiency.

Abstract: Mechanisms for external and distributed protection of Web application data against prying, tampering, and impersonation using cryptographic mechanisms are provided. The protection is offered opaquely so as to not expose the cryptographic mechanism to the Web application. Protection against prying prevents users from looking at data the Web application considers private. When protected against prying, protect data may be sent to the client but the user will not be able to understand it. Protection against tampering, guaranties the Web application that the data it is receiving originated from a trusted source, usually the Web application itself. A user session state stored client-side is a good candidate for tampering protection. Protection against impersonation ensures the Web application that the data it is receiving comes from a specific user.

Abstract: The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups, and their use in treating cardiovascular events and renal insufficiency.

Abstract: The present invention provides inhibitors of kinases, specifically I?B kinases, JAK1, JAK2, JAK3 and TYK2. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting said kinase activity by administering the compound to a patient in need of treatment for myeloproliferative disorders, cancer or NF-?B-mediated diseases.

Abstract: Pyridopyrrolizine and pyridoindolizine derivatives are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.

Abstract: Method to build rich input validation rules to address values not previously validated by type based rules or regular expressions available in current validation engines. These new validation rules have a rich set of ordered validation rule primitives (VRPs) with acceptance VRP or rejection VRP, thus the new validation rules have capabilities to handle complex data values. Also disclosed is method to build a validation rule applied to data elements defined using a Perl regular expression.

Abstract: Method, system and storage medium encoding a computer program for synchronizing a first user session and a second user session in a client-server system. The first user session is between a first Web service and a client and the second user session is between a second Web service and the same client. A request is received with a first session value by the second Web service. an indicator of the first session value is assigned to a shadow, and the shadow is sent in a response to the client. A subsequent request with the shadow and a subsequent session value is received from the client. The indicator is used to verify the subsequent session value at the second Web service. The second user session is terminated if the indicator in the shadow does not correspond to the subsequent session value.

Abstract: The present invention provides novel compounds of Formula I which are antagonists of the C5a receptor. Compounds of the present invention are useful for the treatment of various C5a-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of C5a-mediated diseases using the novel compounds described herein, as well as pharmaceutical compositions containing them.

Abstract: A method of validating parameters of a request from a Web client to a Web application. The validation rules are sent to a Web client, together with a response to a Web client. The parameters in a response are updated by the Web client. The updated parameters are sent in a subsequent request to the Web client, along with the validation rules. The updated parameters are validated using the validation rules in the request, thus achieving stateless validation. The validation rules are preferably digitally signed.

Abstract: The present invention provides novel compounds of Formula I which are antagonists of the C5a receptor. Compounds of the present invention are useful for the treatment of various C5a-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of C5a-mediated diseases using the novel compounds described herein, as well as pharmaceutical compositions containing them.

Abstract: A method of controlling data transfer between a Web client and a Web application by building a response with a target. The target indicates a destination to an impromptu component of the Web application. The target is signed when a response is built. After receiving the response by the Web client; the corresponding a request from the Web client includes the signed target. The request is received by an entry point of the Web application. The entry point has existing validation rules. The validation rules are by-passed when the signed target is verified. The target is restored in the request to the original state; and dispatched to the impromptu component.

Abstract: Method and system for centralized control of data transfers between a Web client and a Web application by receiving a response from the Web application. After determining an offending character is present, cloaking the response from the Web application to a request from a Web client, and sending the cloaked response to the Web client through a security product which otherwise rejects the offending character.